Observation on the main clinical therapeutic effect indexes of LVYE pharmaceutical anti-tumor biological drug ly01008 in phase III

LVYE Pharmaceutical Group announced that its biological antibody drug ly01008 (Avastin ® biological analogue) in the field of tumor had completed a phase III clinical trial in China in May this year, which was compared with the efficacy and safety of Avastin ® and included 648 patients in the group At present, the objective remission rate (ORR), the main therapeutic index, has been observed in this clinical trial The R & D pipeline of LVYE pharmaceutical in the field of tumor has entered into different clinical stages at home and abroad, and the R & D is progressing smoothly The continuous enrichment of the follow-up product lines will continue to strengthen the company's competitiveness in the field of the disease and lay a solid foundation for its rapid expansion of the global market Ly01008 is a recombinant anti VEGF humanized monoclonal antibody injection, which is used for the treatment of non-small cell lung cancer and colorectal cancer It is a biologically similar drug of Avastin, a heavy-duty anticancer drug on the market According to the public financial report data, Avastin's global sales reached CHF 6.849 billion in 2018; in addition, according to iqvia data, Avastin's sales in China reached RMB 1.74 billion in 2018 From the perspective of patient demand, lung cancer and colorectal cancer have become the first and third largest cancer species in China In 2018, there were 774000 new lung cancer cases in China, of which non-small cell lung cancer accounted for 80% Colorectal cancer is second only to lung cancer and gastric cancer in China, with 429000 new cases and 281000 deaths each year The huge and rapidly expanding patient population makes the disease field have far unmet drug demand "We will accelerate the launch of ly01008 in order to meet the treatment needs of more patients," said the management of LVYE Pharmaceutical Group At present, the company's strong marketing ability and broad market coverage in the field of tumor will also provide strong support for the listing of ly01008 Tumor field is one of the core treatment fields focused by the company, and we will continue to increase investment through independent research and development, foreign cooperation and other ways, and continue to promote and enrich the follow-up product line of the disease field " In addition to ly01008, there are many innovative preparations and innovative drugs in the field of cancer at different clinical stages at home and abroad, including the innovative drug zepsyre ® (lurbinectdin), the innovative preparation goserellin acetate sustained-release microspheres for injection, dinozumab biological analogues, Ido / TDO double target inhibitors, car-t therapy and a series of research projects.